Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1986 May;23(5):852–857. doi: 10.1128/jcm.23.5.852-857.1986

Evaluation of live avian-human reassortant influenza A H3N2 and H1N1 virus vaccines in seronegative adult volunteers.

M H Snyder, M L Clements, R F Betts, R Dolin, A J Buckler-White, E L Tierney, B R Murphy
PMCID: PMC268736  PMID: 3711273

Abstract

An avian-human reassortant influenza A virus deriving its genes coding for the hemagglutinin and neuraminidase from the human influenza A/Washington/897/80 (H3N2) virus and its six "internal" genes from the avian influenza A/Mallard/NY/6750/78 (H2N2) virus (i.e., a six-gene reassortant) was previously shown to be safe, infectious, nontransmissible, and immunogenic as a live virus vaccine in adult humans. Two additional six-gene avian-human reassortant influenza viruses derived from the mating of wild-type human influenza A/California/10/78 (H1N1) and A/Korea/1/82 (H3N2) viruses with the avian influenza A/Mallard/NY/78 virus were evaluated in seronegative (hemagglutination inhibition titer, less than or equal to 1:8) adult volunteers for safety, infectivity, and immunogenicity to determine whether human influenza A viruses can be reproducibly attenuated by the transfer of the six internal genes of the avian influenza A/Mallard/NY/78 virus. The 50% human infectious dose was 10(4.9) 50% tissue culture infectious doses for the H1N1 reassortant virus and 10(5.4) 50% tissue culture infectious doses for the H3N2 reassortant virus. Both reassortants were satisfactorily attenuated with only 5% (H1N1) and 2% (H3N2) of infected vaccines receiving less than 400 50% human infectious doses developing illness. Consistent with this level of attenuation, the magnitude of viral shedding after inoculation was reduced 100-fold (H1N1) to 10,000-fold (H3N2) compared with that produced by wild-type virus. The duration of virus shedding by vaccines was one-third that of controls receiving wild-type virus. At 40 to 100 50% human infectious doses, virus-specific immune responses were seen in 77 to 93% of volunteers. When vaccinees who has received 10(7.5) 50% tissue culture infectious doses of the H3N2 vaccine were experimentally challenged with a homologous wild-type human virus only 2 of 19 (11%) vaccinees became ill compared with 7 of 14 (50%) unvaccinated seronegative controls ( P < 0.025; protective efficacy, 79%). Thus, three different virulent human influenza A viruses have been satisfactorily attenuated by the acquisition of the six internal genes of the avian influenza A/Mallard/NY/78 virus. The observation that this donor virus can reproducibly attenuate human influenza A viruses indicates that avian-human influenza A reassortants should be further studied as potential live influenza A virus vaccines.

Full text

PDF
852

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clements M. L., Betts R. F., Maassab H. F., Murphy B. R. Dose response of influenza A/Washington/897/80 (H3N2) cold-adapted reassortant virus in adult volunteers. J Infect Dis. 1984 May;149(5):814–815. doi: 10.1093/infdis/149.5.814. [DOI] [PubMed] [Google Scholar]
  2. Clements M. L., Betts R. F., Murphy B. R. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet. 1984 Mar 31;1(8379):705–708. doi: 10.1016/s0140-6736(84)92222-0. [DOI] [PubMed] [Google Scholar]
  3. Clements M. L., O'Donnell S., Levine M. M., Chanock R. M., Murphy B. R. Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun. 1983 Jun;40(3):1044–1051. doi: 10.1128/iai.40.3.1044-1051.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Johnson P. R., Jr, Feldman S., Thompson J. M., Mahoney J. D., Wright P. F. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol. 1985 Dec;17(4):325–335. doi: 10.1002/jmv.1890170405. [DOI] [PubMed] [Google Scholar]
  5. Murphy B. R., Buckler-White A. J., London W. T., Harper J., Tierney E. L., Miller N. T., Reck L. J., Chanock R. M., Hinshaw V. S. Avian-human reassortant influenza A viruses derived by mating avian and human influenza A viruses. J Infect Dis. 1984 Dec;150(6):841–850. doi: 10.1093/infdis/150.6.841. [DOI] [PubMed] [Google Scholar]
  6. Murphy B. R., Chalhub E. G., Nusinoff S. R., Kasel J., Chanock R. M. Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man. J Infect Dis. 1973 Oct;128(4):479–487. doi: 10.1093/infdis/128.4.479. [DOI] [PubMed] [Google Scholar]
  7. Murphy B. R., Clements M. L., Madore H. P., Steinberg J., O'Donnell S., Betts R., Demico D., Reichman R. C., Dolin R., Maassab H. F. Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers. J Infect Dis. 1984 May;149(5):816–816. doi: 10.1093/infdis/149.5.816. [DOI] [PubMed] [Google Scholar]
  8. Murphy B. R., Clements M. L., Tierney E. L., Black R. E., Stienberg J., Chanock R. M. Dose response of influenza A/Washington/897/80 (H3N2) avian-human reassortant virus in adult volunteers. J Infect Dis. 1985 Jul;152(1):225–229. doi: 10.1093/infdis/152.1.225. [DOI] [PubMed] [Google Scholar]
  9. Murphy B. R., Hinshaw V. S., Sly D. L., London W. T., Hosier N. T., Wood F. T., Webster R. G., Chanock R. M. Virulence of avian influenza A viruses for squirrel monkeys. Infect Immun. 1982 Sep;37(3):1119–1126. doi: 10.1128/iai.37.3.1119-1126.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Murphy B. R., Holley H. P., Jr, Berquist E. J., Levine M. M., Spring S. B., Maassab H. F., Kendal A. P., Chanock R. M. Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain. Infect Immun. 1979 Feb;23(2):253–259. doi: 10.1128/iai.23.2.253-259.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Murphy B. R., Nelson D. L., Wright P. F., Tierney E. L., Phelan M. A., Chanock R. M. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun. 1982 Jun;36(3):1102–1108. doi: 10.1128/iai.36.3.1102-1108.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Murphy B. R., Phelan M. A., Nelson D. L., Yarchoan R., Tierney E. L., Alling D. W., Chanock R. M. Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol. 1981 Mar;13(3):554–560. doi: 10.1128/jcm.13.3.554-560.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Murphy B. R., Sly D. L., Tierney E. L., Hosier N. T., Massicot J. G., London W. T., Chanock R. M., Webster R. G., Hinshaw V. S. Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. Science. 1982 Dec 24;218(4579):1330–1332. doi: 10.1126/science.6183749. [DOI] [PubMed] [Google Scholar]
  14. Phelan M. A., Mayner R. E., Bucher D. J., Ennis F. A. Purification of influenza virus glycoproteins for the preparation and standardization of immunological potency testing reagents. J Biol Stand. 1980;8(3):233–242. doi: 10.1016/s0092-1157(80)80039-4. [DOI] [PubMed] [Google Scholar]
  15. Tian S. F., Buckler-White A. J., London W. T., Reck L. J., Chanock R. M., Murphy B. R. Nucleoprotein and membrane protein genes are associated with restriction of replication of influenza A/Mallard/NY/78 virus and its reassortants in squirrel monkey respiratory tract. J Virol. 1985 Mar;53(3):771–775. doi: 10.1128/jvi.53.3.771-775.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Webster R. G., Yakhno M., Hinshaw V. S., Bean W. J., Murti K. G. Intestinal influenza: replication and characterization of influenza viruses in ducks. Virology. 1978 Feb;84(2):268–278. doi: 10.1016/0042-6822(78)90247-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES